A comprehensive guide to patient-focused management strategies for Crohn disease.
In Crohn disease, a vigorous inflammatory cascade is caused by the overactivation of helper T-cells in the gastrointestinal system. The results of this inflammation manifest themselves as the symptoms of Crohn disease. This article describes the pathophysiology of Crohn disease as well as multiple pharmacologic and nonpharmacologic interventions that may assist patients with Crohn disease in preventing exacerbations and maintaining longer remissions.
Fow
Jennifer
J
Yale University School of Nursing, New Haven, Connecticut, USA.
Grossman
Sheila
S
D000636:Aminosalicylic Acids / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D003424:Crohn Disease / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control* / Q000523:psychology; D005395:Fish Oils / Q000627:therapeutic use; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D000069285:Infliximab; D024802:Nurse's Role / Q000523:psychology; D009723:Nurse-Patient Relations; D018529:Nutritional Support / Q000379:methods; D010347:Patient Care Planning / Q000458:organization & administration; D010358:Patient Participation / Q000379:methods / Q000523:psychology; D018802:Patient-Centered Care / Q000458:organization & administration*; D008517:Phytotherapy / Q000379:methods; D019936:Probiotics / Q000627:therapeutic use; D012074:Remission Induction; D012307:Risk Factors
D000636:Aminosalicylic Acids; D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D005395:Fish Oils; D005765:Gastrointestinal Agents; D007155:Immunologic Factors; D000069285:Infliximab; D001379:Azathioprine